New Italian study shows that K.O.S has positive effects on allergic rhinitis

The results of the new investigator-initiated study titled "Effectiveness of Kinetic Oscillation Stimulation Treatment in Persistent Moderate-Severe Allergic Rhinitis Compared to Medical Therapy" demonstrate that Chordate's K.O.S treatment improves nasal airflow more effectively than medical therapy alone in cases of persistent moderate to severe allergic rhinitis. Symptoms such as congestion, runny nose, itching, and sneezing significantly decreased in patients who received medical treatment in combination with K.O.S.

"We have not previously investigated the effects with K.O.S on allergic rhinitis in particular, so these results are very positive and potentially open up new opportunities for the company," says Jan Hermansson, Chief Medical Officer of Chordate.

The patients in this study were diagnosed using skin prick tests on the arm or blood tests to confirm allergies, including allergies to dust mites, among others.

"This is important new information for physicians treating patients where allergens such as pollen and dust mites are frequently present. Patients with rhinitis often have a combination of allergic and non-allergic rhinitis, which may be a reason why a K.O.S-treatment combination provides the indicated improvement,"

The study was conducted by, among others, Dr. Lino Di Rienzo Businco, and was published in Journal of Otolaryngology Research & Reports.

More press releases

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact